Our findings presented here provide evidence that carfilzomib may overcome the 5-FU resistance in colorectal cancer induced by the NF-κB/β-catenin/ZEB1 activation that is mediated by cNrf2-induced PSMD4 expression. Here, ZEB1 is linked to colorectal cancer.